Dawnrays Pharmaceutical Holdings Ltd. AI Stock Analysis
Want to see HK:2348 full AI Analyst Report?
Dawnrays Pharmaceutical Holdings Ltd. (2348) AI Stock Analysis
Dawnrays Pharmaceutical Holdings Ltd.
(HKEX:2348)
The score is supported primarily by a strong balance sheet, improving cash flow, and highly attractive valuation. Weak technical momentum and declining margins constrain the overall rating.
Dawnrays Pharmaceutical Holdings Ltd. (2348) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.36B
- Dividend Yield
- 7.00%
- Average Volume (3M)
- 402.05K
- Price to Earnings (P/E)
- 5.0
- Beta (1Y)
- 0.26
- Revenue Growth
- 6.55%
- EPS Growth
- 36.62%
- Country
- Hong Kong
- Employees
- 1,074
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Dawnrays Pharmaceutical Holdings Ltd. Business Overview & Revenue Model
Company Description
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets...
How the Company Makes Money
The company primarily makes money by selling pharmaceutical products it develops and/or manufactures through commercial distribution to end customers such as hospitals, clinics, pharmacies, and/or pharmaceutical distributors. Revenue is generally gen...
Dawnrays Pharmaceutical Holdings Ltd. Financial Statement Overview
Summary
Strong balance sheet with very low leverage and growing equity supports the score. Cash flow is improving, but margin erosion, lower ROE, and profit volatility limit upside.
Income Statement
72PositiveBalance Sheet
88Very PositiveCash Flow
75Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.14B | 1.23B | 1.06B | 1.15B | 1.28B | 1.17B |
| Gross Profit | 544.47M | 557.40M | 577.63M | 641.52M | 766.68M | 675.36M |
| EBITDA | 361.10M | 347.57M | 308.67M | 498.94M | 505.19M | 438.31M |
| Net Income | 231.04M | 213.97M | 564.94M | 326.00M | 358.06M | 358.18M |
Balance Sheet | ||||||
| Total Assets | 3.99B | 4.01B | 4.01B | 3.62B | 3.67B | 3.34B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.58B | 1.37B | 1.07B | 993.04M | 830.22M |
| Total Debt | 4.48M | 77.51M | 34.72M | 120.53M | 8.41M | 23.52M |
| Total Liabilities | 552.42M | 621.75M | 682.61M | 763.42M | 1.02B | 941.70M |
| Stockholders Equity | 3.43B | 3.39B | 3.32B | 2.85B | 2.64B | 2.38B |
Cash Flow | ||||||
| Free Cash Flow | 298.09M | 236.01M | 44.58M | 126.39M | 229.90M | 80.07M |
| Operating Cash Flow | 376.95M | 355.41M | 220.20M | 338.40M | 434.27M | 393.14M |
| Investing Cash Flow | -237.08M | -368.80M | 205.17M | -387.57M | -175.01M | -284.20M |
| Financing Cash Flow | -64.19M | -54.99M | -189.44M | 2.07M | -92.70M | -129.75M |
Dawnrays Pharmaceutical Holdings Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2348, the sentiment is Negative. The current price of 0.90 is below the 20-day moving average (MA) of 0.93, below the 50-day MA of 0.95, and below the 200-day MA of 1.02, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 35.45 is Neutral, neither overbought nor oversold. The STOCH value of 19.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2348.
Dawnrays Pharmaceutical Holdings Ltd. Peers Comparison
Overall Rating
- HK:234873Outperform
HK:216173Outperform
HK:263370Outperform
HK:095068Neutral
HK:256142Neutral
HK:165240Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2348 | 73Outperform | HKD 1.36B | 5.01 | 6.78% | 7.00% | 6.55% | 36.62% |
| HK:2161 | 73Outperform | HKD 1.26B | 6.14 | 18.70% | 11.13% | 6.69% | 2.45% |
| HK:2633 | 70Outperform | HKD 1.75B | 6.09 | 13.26% | 9.83% | -0.47% | -0.40% |
| HK:0950 | 68Neutral | HKD 618.28M | 3.71 | 8.02% | 5.50% | 7.05% | 22.46% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2561 | 42Neutral | HKD 1.42B | -4.81 | -33.42% | ― | ― | ― |
| HK:1652 | 40Underperform | HKD 661.70M | -239.01 | -0.66% | ― | 18.14% | 98.32% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2348 | Dawnrays Pharmaceutical Holdings Ltd. | 0.90 | -0.20 | -18.26% | |
| HK:0950 | Lee's Pharmaceutical Holdings Limited | 1.05 | -0.66 | -38.60% | |
| HK:1652 | Fusen Pharmaceutical Co., Ltd. | 0.90 | 0.03 | 3.45% | |
| HK:2161 | JBM (Healthcare) Ltd. | 1.53 | -1.15 | -42.87% | |
| HK:2633 | Jacobson Pharma Corporation Limited | 0.92 | -0.43 | -31.85% | |
| HK:2561 | VISEN Pharmaceuticals | 12.46 | -20.94 | -62.69% |
Dawnrays Pharmaceutical Holdings Ltd. Corporate Events
Dawnrays Pharmaceutical Boosts Profit Margins Despite Revenue Decline in First Half 2026
Dawnrays Pharmaceutical (Holdings) Limited reported unaudited interim results for the six months ended 30 June 2026 that show lower top-line but stronger profitability. Revenue fell 13.4% year-on-year to RMB545.8 million, yet gross profit margin impr...
Dawnrays Pharmaceutical Declares Interim Dividend for First Half of 2026
Dawnrays Pharmaceutical (Holdings) Ltd. has declared an interim ordinary dividend of HKD 0.015 per share for the six months ended 30 June 2026, payable in Hong Kong dollars on 9 October 2026. The ex-dividend date is set for 22 September, with the reg...
Dawnrays Pharmaceutical Sets Board Meeting to Approve Interim Results and Mull Dividend
Dawnrays Pharmaceutical (Holdings) Limited has scheduled a board meeting for 28 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider whether to declare an interim dividend, signalin...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026